Log in to your Inderes Free account to see all free content on this page.

Lundbeck

44.50 DKK

+1.09 %

Less than 1K followers

HLUN B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Investor consensus

+1.09 %

-3.89 %

+5.85 %

+20.34 %

+7.70 %

+0.82 %

+67.10 %

+21.78 %

+80.89 %

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Market cap

44.31B DKK

Turnover

10.12M DKK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

All

Press releases

ShowingAll content types

Press release12/2/2025, 7:00 AM

H. Lundbeck A/S: Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

Regulatory press release11/26/2025, 4:23 PM

H. Lundbeck A/S: ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 "MAR" RULES (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE "IRISH TAKEOVER RULES")

Regulatory press release11/14/2025, 11:44 AM

H. Lundbeck A/S: ANNOUNCEMENT FOR THE PURPOSES OF RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE "IRISH TAKEOVER RULES") AND MAR ARTICLE 17 (INSIDE INFORMATION)

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release11/14/2025, 7:55 AM

H. Lundbeck A/S: Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine

Regulatory press release11/11/2025, 2:34 PM

H. Lundbeck A/S: Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti[®] and Rexulti[®] driven by additional investments

Regulatory press release11/11/2025, 2:21 PM

H. Lundbeck A/S: Lundbeck raises financial guidance for 2025

Press release10/27/2025, 8:00 AM

H. Lundbeck A/S: Lundbeck and OpenAI join forces to unlock innovation and boost productivity

Press release10/20/2025, 7:00 AM

H. Lundbeck A/S: Lundbeck and Contera Pharma announce research collaboration to advance RNA-targeting medicines for serious neurological conditions

Press release10/13/2025, 6:00 AM

H. Lundbeck A/S: Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies

Press release10/2/2025, 7:00 AM

H. Lundbeck A/S: Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

Regulatory press release9/20/2025, 6:00 AM

H. Lundbeck A/S: Otsuka and Lundbeck receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD

Press release9/11/2025, 6:00 AM

H. Lundbeck A/S: Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine

Press release9/9/2025, 12:30 PM

H. Lundbeck A/S: Lundbeck sharpens commercial focus in line with strategy, initiates partnering in 27 markets by end-2025

Press release8/25/2025, 7:00 AM

H. Lundbeck A/S: Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy

Regulatory press release8/13/2025, 4:40 PM

H. Lundbeck A/S: Guidance raised based on solid H1 results and continued strong expectations for the full year 2025

Regulatory press release8/13/2025, 4:34 PM

H. Lundbeck A/S: Lundbeck raises financial guidance for 2025

Press release7/18/2025, 9:24 PM

H. Lundbeck A/S: Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting for the Treatment of Post-Traumatic Stress Disorder (PTSD)

Press release6/24/2025, 6:00 AM

H. Lundbeck A/S: Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Press release6/21/2025, 11:25 AM

H. Lundbeck A/S: New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

Press release6/21/2025, 11:20 AM

H. Lundbeck A/S: New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.